Anil P.  Ranganath net worth and biography

Anil Ranganath Biography and Net Worth

Insider of TransMedics Group
Anil Ranganath joins TransMedics with over 15 years of experience in the life sciences and biotechnology tools industries. Prior to joining TransMedics, Mr. Ranganath served multiple roles of increasing scope and responsibility at Waters Corporation. Most recently, Mr. Ranganath served as Vice President, Deputy General Counsel for Waters, managing legal affairs, and serving as a trusted advisor on Waters’ strategic, tactical, and operational plans. He began his legal career as an Associate at Brown Rudnick LLP, representing life sciences and biotechnology companies on corporate and intellectual property matters. Mr. Ranganath holds a Juris Doctorate from Suffolk University Law School and a Bachelor’s degree in Computer Science from Worcester Polytechnic Institute.

What is Anil P. Ranganath's net worth?

The estimated net worth of Anil P. Ranganath is at least $686,539.60 as of August 7th, 2024. Mr. Ranganath owns 8,893 shares of TransMedics Group stock worth more than $686,540 as of November 21st. This net worth estimate does not reflect any other assets that Mr. Ranganath may own. Learn More about Anil P. Ranganath's net worth.

How do I contact Anil P. Ranganath?

The corporate mailing address for Mr. Ranganath and other TransMedics Group executives is 200 MINUTEMAN ROAD SUITE 302, ANDOVER MA, 01810. TransMedics Group can also be reached via phone at (978) 552-0900 and via email at [email protected]. Learn More on Anil P. Ranganath's contact information.

Has Anil P. Ranganath been buying or selling shares of TransMedics Group?

Anil P. Ranganath has not been actively trading shares of TransMedics Group during the last quarter. Most recently, Anil P. Ranganath sold 4,289 shares of the business's stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $152.20, for a transaction totalling $652,785.80. Following the completion of the sale, the insider now directly owns 8,893 shares of the company's stock, valued at $1,353,514.60. Learn More on Anil P. Ranganath's trading history.

Who are TransMedics Group's active insiders?

TransMedics Group's insider roster includes John Carey (VP), Nicholas Corcoran (Insider), Laura Damme (VP), Stephen Gordon (CFO), Waleed Hassanein (CEO), Edwin Kania, Jr. (Director), Tamer Khayal (Insider), Miriam Provost (VP), and Anil Ranganath (Insider). Learn More on TransMedics Group's active insiders.

Are insiders buying or selling shares of TransMedics Group?

In the last year, insiders at the sold shares 45 times. They sold a total of 477,855 shares worth more than $53,882,883.25. The most recent insider tranaction occured on November, 5th when Director Edward M Basile sold 6,750 shares worth more than $563,962.50. Insiders at TransMedics Group own 7.0% of the company. Learn More about insider trades at TransMedics Group.

Information on this page was last updated on 11/5/2024.

Anil P. Ranganath Insider Trading History at TransMedics Group

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/7/2024Sell4,289$152.20$652,785.808,893View SEC Filing Icon  
6/5/2024Sell703$135.21$95,052.638,809View SEC Filing Icon  
See Full Table

Anil P. Ranganath Buying and Selling Activity at TransMedics Group

This chart shows Anil P Ranganath's buying and selling at TransMedics Group by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

TransMedics Group Company Overview

TransMedics Group logo
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Read More

Today's Range

Now: $77.20
Low: $75.61
High: $81.09

50 Day Range

MA: $122.08
Low: $77.20
High: $165.98

2 Week Range

Now: $77.20
Low: $66.76
High: $177.37

Volume

2,889,274 shs

Average Volume

2,355,708 shs

Market Capitalization

$2.59 billion

P/E Ratio

82.13

Dividend Yield

N/A

Beta

2.08